Skip to main content

Advertisement

Table 13 Whole blood markers

From: A buffered form of creatine does not promote greater changes in muscle creatine content, body composition, or training adaptations than creatine monohydrate

Marker N Group Day   p-level
    0 7 28   
WBC (x103/ul) 9 KA-L 5.73 ± 0.6 6.13 ± 0.5 6.17 ± 1.5 Group 0.95
  12 KA-H 5.83 ± 1.1 5.76 ± 0.9 6.36 ± 1.1 Time 0.16
  12 CrM 5.97 ± 1.2 5.73 ± 1.0 5.98 ± 1.2 G x T 0.45
RBC (x106/ul) 9 KA-L 5.44 ± 0.4 5.38 ± 0.5 5.44 ± 0.3 Group 0.28
  12 KA-H 5.10 ± 0.4 5.18 ± 0.3 5.23 ± 0.3 Time 0.91
  12 CrM 5.42 ± 0.5 5.41 ± 0.5 5.35 ± 0.7 G x T 0.64
Hematocrit (%) 9 KA-L 48.4 ± 3.4 47.9 ± 4.3 48.1 ± 2.9 Group 0.17
  12 KA-H 46.5 ± 3.2 47.0 ± 2.8 47.4 ± 1.8 Time 0.96
  12 CrM 45.9 ± 2.3 46.1 ± 2.5 45.2 ± 5.4 G x T 0.65
Hemoglobin (g/dl) 9 KA-L 16.0 ± 1.6 16.0 ± 1.6 16.0 ± 1.2 Group 0.21
  12 KA-H 15.2 ± 1.2 15.7 ± 1.0 15.6 ± 0.7 Time 0.60
  12 CrM 15.1 ± 0.9 15.2 ± 1.1 14.9 ± 2.0 G x T 0.62
MCV (fL) 9 KA-L 89.0 ± 2.8 88.9 ± 2.9 88.3 ± 2.8 Group 0.10
  12 KA-H 91.1 ± 3.5 90.8 ± 3.1 90.7 ± 3.6 Time 0.03
  12 CrM 85.4 ± 9.2 85.7 ± 9.5 85.0 ± 9.1 G x T 0.56
MCH (pg/cell) 9 KA-L 29.4 ± 1.5 29.6 ± 1.2 29.3 ± 1.2 Group 0.34
  12 KA-H 29.8 ± 1.6 30.2 ± 1.5 28.4 ± 4.9 Time 0.20
  12 CrM 28.1 ± 3.5 28.3 ± 3.7 27.9 ± 3.3 G x T 0.44
MCHC (g/dl) 9 KA-L 33.0 ± 1.3 33.3 ± 0.9 33.2 ± 0.9 Group 0.73
  12 KA-H 32.8 ± 0.9 33.3 ± 0.8 32.9 ± 0.6 Time 0.22
  12 CrM 32.9 ± 1.1 32.9 ± 1.3 32.9 ± 0.8 G x T 0.68
RBCDW (%) 9 KA-L 13.0 ± 0.5 13.0 ± 0.9 12.9 ± 0.7 Group 0.34
  12 KA-H 13.8 ± 1.1 13.7 ± 1.0 13.5 ± 1.5 Time 0.41
  12 CrM 13.7 ± 1.4 13.7 ± 1.7 13.6 ± 1.6 G x T 0.92
Platelet Count (x103/ul) 9 KA-L 266 ± 45 266 ± 52 280 ± 45 Group 0.12
  12 KA-H 253 ± 54 248 ± 62 269 ± 65 Time 0.32
  12 CrM 222 ± 69 222 ± 74 216 ± 65 G x T 0.48
  1. Values are means ± standard deviations. White and red cell whole blood markers were analyzed by MANOVA with repeated measures. Greenhouse-Geisser time and group x time (G x T) interaction p-levels are reported with univariate group p-levels.